Literature DB >> 6401442

Nifedipine in hypertensive emergencies.

O Bertel, D Conen, E W Radü, J Müller, C Lang, U C Dubach.   

Abstract

The effects and safety of using oral nifedipine 10-20 mg as acute antihypertensive treatment were studied in a single-blind placebo-controlled study of 25 consecutive patients with very high blood pressure requiring emergency reduction. In addition the effect of this treatment on cerebral blood flow was investigated using xenon-133 in 10 patients randomly allocated to receive oral nifedipine or intravenous clonidine. Whereas placebo did not alter the blood pressure, oral nifedipine significantly reduced the systolic and diastolic blood pressures in all 25 patients (from 221 +/- 22/126 +/- 14 mm Hg to 152 +/- 20/89 +/- 12 mm Hg after 30 minutes, p less than 0.001). Heart rate increased from 74 +/- 11 to 84 +/- 11 beats/minute (p less than 0.01); this effect was inversely related to age (r = -0.65, p less than 0.01). The falls in systolic and diastolic blood pressures were closely related to the blood pressures before treatment ) r = 0.67, p less than 0.001 for systolic, and r = -0.58, p less than 0.01 for diastolic values). No serious unwanted effects were observed. Measurement of cerebral blood flow after nifedipine showed an increase in flow in four out of five patients. Clonidine, by contrast, reduced cerebral blood flow in all patients by up to 28%. Nifedipine is a simple, effective, and safe alternative drug for managing hypertensive emergencies, especially when continuous monitoring of the patient cannot be guaranteed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6401442      PMCID: PMC1546618          DOI: 10.1136/bmj.286.6358.19

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  11 in total

1.  Ischaemic brain damage of cerebral perfusion failure type after treatment of severe hypertension.

Authors:  D I Graham
Journal:  Br Med J       Date:  1975-12-27

2.  Side effects of diazoxide.

Authors:  G K Kumar; F C Dastoor; J R Robayo; M A Razzaque
Journal:  JAMA       Date:  1976-01-19       Impact factor: 56.272

3.  Letter: Toxicity of sodium nitroprusside.

Authors:  A J Merrifield; M D Blundell
Journal:  Br J Anaesth       Date:  1974-04       Impact factor: 9.166

4.  Improved method for noninvasive measurement of regional cerebral blood flow by 133Xenon inhalation. Part I: description of method and normal values obtained in healthy volunteers.

Authors:  J S Meyer; N Ishihara; V D Deshmukh; H Naritomi; F Sakai; M C Hsu; P Pollack
Journal:  Stroke       Date:  1978 May-Jun       Impact factor: 7.914

Review 5.  Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications.

Authors:  P H Stone; E M Antman; J E Muller; E Braunwald
Journal:  Ann Intern Med       Date:  1980-12       Impact factor: 25.391

6.  Nifedipine, a new antihypertensive with rapid action.

Authors:  M Guazzi; M T Olivari; A Polese; C Fiorentini; F Magrini; P Moruzzi
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

7.  Cerebral complications in the treatment of accelerated hypertension.

Authors:  J G Ledingham; B Rajagopalan
Journal:  Q J Med       Date:  1979-01

8.  Decreased Beta-adrenoreceptor responsiveness as related to age, blood pressure, and plasma catecholamines in patients with essential hypertension.

Authors:  O Bertel; F R Bühler; W Kiowski; B E Lütold
Journal:  Hypertension       Date:  1980 Mar-Apr       Impact factor: 10.190

Review 9.  Drugs five years later: clonidine.

Authors:  J Lowenstein
Journal:  Ann Intern Med       Date:  1980-01       Impact factor: 25.391

10.  Efficacy of sublingual nifedipine in the acute treatment of systemic hypertension.

Authors:  N Beer; I Gallegos; A Cohen; N Klein; E Sonnenblick; W Frishman
Journal:  Chest       Date:  1981-05       Impact factor: 9.410

View more
  34 in total

1.  Pharmacokinetics of nifedipine derived from a new retard tablet formulation.

Authors:  A Avgerinos; J W Gorrod
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Oct-Dec       Impact factor: 2.441

Review 2.  Use of nifedipine in hypertension and Raynaud's phenomenon.

Authors:  W Kiowski; P Erne; F R Bühler
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

3.  Unreviewed reports.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1985-04-13

Review 4.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

5.  Rupture of a cerebral aneurysm associated with nifedipine treatment.

Authors:  J S Gill; A V Zezulka; P M Horrocks
Journal:  Postgrad Med J       Date:  1986-11       Impact factor: 2.401

6.  Effect of nifedipine on arterial hypoxaemia occurring after methacholine challenge in asthma.

Authors:  E Ballester; J Roca; R Rodriguez-Roisin; A Agusti-Vidal
Journal:  Thorax       Date:  1986-06       Impact factor: 9.139

7.  [Effect of the Ca antagonist nimodipine on global and regional cerebrovascular circulation].

Authors:  M R Gaab; C P Rode; E H Schakel; I Haubitz; J Bockhorn; A Brawanski
Journal:  Klin Wochenschr       Date:  1985-01-02

Review 8.  Vasodilators during cerebral aneurysm surgery.

Authors:  K Abe
Journal:  Can J Anaesth       Date:  1993-08       Impact factor: 5.063

9.  Treatment of hypertensive emergency. Comparison of a new dosage form of the calcium antagonist nitrendipine with nifedipine capsules.

Authors:  G Rohr; P Reimnitz; P Blanke
Journal:  Intensive Care Med       Date:  1994       Impact factor: 17.440

Review 10.  Drug therapy of renovascular hypertension.

Authors:  Talma Rosenthal
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.